Biocon shares in focus after subsidiary launches biosimilar alternative to Stelara in the US

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering a cost-effective option. This is Biocon's first US product launch since becoming a global biosimilars organization. Biocon shares, currently at Rs 321, have declined 13% year-to-date but gained 42% in the last two years.